MovDisordV3, Main, Exploration, bibRecord, 004041

Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT

Identifieur interne : 004041 ( Main/Exploration ); précédent : 004040; suivant : 004042

Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT

Auteurs : Walter Pirker [Autriche] ; Iris Holler [Autriche] ; Willibald Gerschlager [Autriche] ; Susanne Asenbaum [Autriche] ; Georg Zettinig [Autriche] ; Thomas Brücke [Autriche]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-11.

RBID : ISTEX:F72AC8D06EE5BAC470267D06E4174BE80D842535

Descripteurs français

Pascal (Inist)
- Emission, Evolution, Homme, Parkinson maladie, Photon, Tomoscintigraphie, Transmission dopaminergique.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Binding Sites, Cocaine (analogs & derivatives), Cocaine (diagnostic use), Cocaine (pharmacokinetics), Cognition Disorders (diagnosis), Corpus Striatum (metabolism), Corpus Striatum (physiopathology), Disease Progression, Dopamine Plasma Membrane Transport Proteins, Dopaminergic transmission, Emission, Emission tomography, Evolution, Female, Follow-Up Studies, Human, Humans, Male, Membrane Glycoproteins, Membrane Transport Proteins (metabolism), Middle Aged, Nerve Tissue Proteins, Neuropsychological Tests, Parkinson Disease (diagnosis), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Photon, Radiopharmaceuticals (pharmacokinetics), Radiopharmaceuticals (therapeutic use), Severity of Illness Index, Time Factors, Tomography, Emission-Computed, Single-Photon, [123I]β‐CIT, disease progression, single photon emission computerized tomography (SPECT).
MESH :
- chemical , analogs & derivatives : Cocaine.
- chemical , diagnostic use : Cocaine.
- chemical , metabolism : Membrane Transport Proteins.
- chemical , pharmacokinetics : Cocaine, Radiopharmaceuticals.
- diagnosis : Cognition Disorders, Parkinson Disease.
- metabolism : Corpus Striatum, Parkinson Disease.
- physiopathology : Corpus Striatum, Parkinson Disease.
- chemical , therapeutic use : Radiopharmaceuticals.
- Binding Sites, Disease Progression, Dopamine Plasma Membrane Transport Proteins, Female, Follow-Up Studies, Humans, Male, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Neuropsychological Tests, Severity of Illness Index, Time Factors, Tomography, Emission-Computed, Single-Photon.

Abstract

Recent imaging studies suggest a rapid degeneration of the dopaminergic system in early Parkinson's disease (PD), followed by a slowing of the degenerative process in advanced disease. In the present study, a group of early‐stage PD patients underwent three sequential [123I]β‐CIT SPECT studies to assess the decline of striatal dopamine transporter binding over a 5‐year period. Twenty‐one of a cohort of 24 early PD patients who participated in an earlier longitudinal β‐CIT SPECT imaging study [Mov Disord 2002;17:45–53] were included. Scan intervals were 26 ± 11 months (scan 1–2) and 38 ± 15 months (scan 2–3), respectively. The relative annual rate of decline of striatal β‐CIT binding from age‐expected normal values at the time of Scan 1 was used as primary outcome variable. The relative annual decline of striatal binding from Scan 1 to Scan 2 (4.5 ± 4.6%) and from Scan 2 to Scan 3 (3.0 ± 3.0%) was not significantly different. The non‐significant difference in progression rate was due mainly to the rapid early decline of striatal binding in 1 patient who subsequently developed a severe dysexecutive dementia syndrome. These data are not suggestive of substantial change in the course of dopaminergic degeneration in PD within the first 5 to 7 years after symptom onset. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/F72AC8D06EE5BAC470267D06E4174BE80D842535/fulltext/pdf

DOI: 10.1002/mds.10531

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT</title>
<author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name>
</author>
<author><name sortKey="Holler, Iris" sort="Holler, Iris" uniqKey="Holler I" first="Iris" last="Holler">Iris Holler</name>
</author>
<author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
</author>
<author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
</author>
<author><name sortKey="Zettinig, Georg" sort="Zettinig, Georg" uniqKey="Zettinig G" first="Georg" last="Zettinig">Georg Zettinig</name>
</author>
<author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F72AC8D06EE5BAC470267D06E4174BE80D842535</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10531</idno>
<idno type="url">https://api.istex.fr/document/F72AC8D06EE5BAC470267D06E4174BE80D842535/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000628</idno>
<idno type="wicri:Area/Istex/Curation">000628</idno>
<idno type="wicri:Area/Istex/Checkpoint">002971</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Pirker W:measuring:the:rate</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14639666</idno>
<idno type="wicri:Area/PubMed/Corpus">003643</idno>
<idno type="wicri:Area/PubMed/Curation">003643</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003733</idno>
<idno type="wicri:Area/Ncbi/Merge">000C21</idno>
<idno type="wicri:Area/Ncbi/Curation">000C21</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C21</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Pirker W:measuring:the:rate</idno>
<idno type="wicri:Area/Main/Merge">005C64</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0130784</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002291</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A30</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002408</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Pirker W:measuring:the:rate</idno>
<idno type="wicri:Area/Main/Merge">005F54</idno>
<idno type="wicri:Area/Main/Curation">004041</idno>
<idno type="wicri:Area/Main/Exploration">004041</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT</title>
<author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Holler, Iris" sort="Holler, Iris" uniqKey="Holler I" first="Iris" last="Holler">Iris Holler</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Nuclear Medicine, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zettinig, Georg" sort="Zettinig, Georg" uniqKey="Zettinig G" first="Georg" last="Zettinig">Georg Zettinig</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Nuclear Medicine, University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Wilhelminenspital, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-11">2003-11</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1266">1266</biblScope>
<biblScope unit="page" to="1272">1272</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">F72AC8D06EE5BAC470267D06E4174BE80D842535</idno>
<idno type="DOI">10.1002/mds.10531</idno>
<idno type="ArticleID">MDS10531</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Binding Sites</term>
<term>Cocaine (analogs & derivatives)</term>
<term>Cocaine (diagnostic use)</term>
<term>Cocaine (pharmacokinetics)</term>
<term>Cognition Disorders (diagnosis)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Disease Progression</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Dopaminergic transmission</term>
<term>Emission</term>
<term>Emission tomography</term>
<term>Evolution</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins (metabolism)</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Photon</term>
<term>Radiopharmaceuticals (pharmacokinetics)</term>
<term>Radiopharmaceuticals (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>[123I]β‐CIT</term>
<term>disease progression</term>
<term>single photon emission computerized tomography (SPECT)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cocaine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Cocaine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Transport Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Cocaine</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Binding Sites</term>
<term>Disease Progression</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Membrane Glycoproteins</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins</term>
<term>Neuropsychological Tests</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Emission</term>
<term>Evolution</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Photon</term>
<term>Tomoscintigraphie</term>
<term>Transmission dopaminergique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent imaging studies suggest a rapid degeneration of the dopaminergic system in early Parkinson's disease (PD), followed by a slowing of the degenerative process in advanced disease. In the present study, a group of early‐stage PD patients underwent three sequential [123I]β‐CIT SPECT studies to assess the decline of striatal dopamine transporter binding over a 5‐year period. Twenty‐one of a cohort of 24 early PD patients who participated in an earlier longitudinal β‐CIT SPECT imaging study [Mov Disord 2002;17:45–53] were included. Scan intervals were 26 ± 11 months (scan 1–2) and 38 ± 15 months (scan 2–3), respectively. The relative annual rate of decline of striatal β‐CIT binding from age‐expected normal values at the time of Scan 1 was used as primary outcome variable. The relative annual decline of striatal binding from Scan 1 to Scan 2 (4.5 ± 4.6%) and from Scan 2 to Scan 3 (3.0 ± 3.0%) was not significantly different. The non‐significant difference in progression rate was due mainly to the rapid early decline of striatal binding in 1 patient who subsequently developed a severe dysexecutive dementia syndrome. These data are not suggestive of substantial change in the course of dopaminergic degeneration in PD within the first 5 to 7 years after symptom onset. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Vienne (Autriche)</li>
</region>
<settlement><li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name>
</region>
<name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
<name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name>
<name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name>
<name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name>
<name sortKey="Holler, Iris" sort="Holler, Iris" uniqKey="Holler I" first="Iris" last="Holler">Iris Holler</name>
<name sortKey="Zettinig, Georg" sort="Zettinig, Georg" uniqKey="Zettinig G" first="Georg" last="Zettinig">Georg Zettinig</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004041 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004041 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F72AC8D06EE5BAC470267D06E4174BE80D842535
   |texte=   Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT

Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.